(CHD) Church & Dwight - Ratings and Ratios
Baking Soda, Laundry Detergent, Toothpaste, Condoms, Supplements
Dividends
| Dividend Yield | 1.39% |
| Yield on Cost 5y | 1.43% |
| Yield CAGR 5y | 4.30% |
| Payout Consistency | 87.4% |
| Payout Ratio | 34.4% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 19.0% |
| Value at Risk 5%th | 32.2% |
| Relative Tail Risk | 3.05% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.21 |
| Alpha | -26.62 |
| CAGR/Max DD | 0.08 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.445 |
| Beta | 0.046 |
| Beta Downside | 0.046 |
| Drawdowns 3y | |
|---|---|
| Max DD | 27.28% |
| Mean DD | 6.82% |
| Median DD | 4.88% |
Description: CHD Church & Dwight October 16, 2025
Church & Dwight Co. (NYSE: CHD) manufactures and markets a diversified portfolio of household, personal-care, and specialty products across three operating segments-Consumer Domestic, Consumer International, and Specialty Products. Its flagship ARM & HAMMER line spans baking-soda-based cleaners, cat litter, and laundry detergents, while the TROJAN brand dominates the condom market and OXICLEAN supplies stain-removing solutions. The company also sells niche health-care items (e.g., FIRST RESPONSE pregnancy tests) and animal-nutrition additives such as BIO-CHLOR and CERTILLUS.
In FY 2023 the firm reported revenue of roughly $5.5 billion, with the ARM & HAMMER household segment contributing about 55 % of sales and delivering an operating margin near 17 %. Net income grew 8 % year-over-year, reflecting modest pricing power in a high-inflation environment and cost-saving initiatives in its supply chain. The specialty animal-feed division, though only ~5 % of total revenue, has a higher gross margin (≈30 %) and benefits from rising protein-demand in emerging markets-a key sector driver.
CHD’s distribution model blends traditional brick-and-mortar channels (supermarkets, mass merchandisers, drugstores) with expanding e-commerce platforms, a trend that has accelerated post-COVID and now accounts for roughly 12 % of total sales. Assuming continued consumer-goods inflation stays within the 3-4 % range, the company’s pricing elasticity suggests earnings could sustain a 5-6 % annual growth rate, but a slowdown in discretionary spending would materially pressure margins.
For a deeper dive into CHD’s valuation metrics and scenario analysis, the ValueRay platform offers a concise, data-driven overview.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (782.5m TTM) > 0 and > 6% of Revenue (6% = 368.5m TTM) |
| FCFTA 0.11 (>2.0%) and ΔFCFTA 1.12pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 2.11% (prev 12.72%; Δ -10.61pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.13 (>3.0%) and CFO 1.14b > Net Income 782.5m (YES >=105%, WARN >=100%) |
| Net Debt (2.07b) to EBITDA (1.39b) ratio: 1.49 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.09 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (245.9m) change vs 12m ago 0.53% (target <= -2.0% for YES) |
| Gross Margin 44.44% (prev 45.65%; Δ -1.22pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 68.96% (prev 69.85%; Δ -0.89pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 9.73 (EBITDA TTM 1.39b / Interest Expense TTM 117.0m) >= 6 (WARN >= 3) |
Altman Z'' 4.83
| (A) 0.01 = (Total Current Assets 1.63b - Total Current Liabilities 1.50b) / Total Assets 9.14b |
| (B) 0.73 = Retained Earnings (Balance) 6.70b / Total Assets 9.14b |
| (C) 0.13 = EBIT TTM 1.14b / Avg Total Assets 8.91b |
| (D) 1.42 = Book Value of Equity 6.97b / Total Liabilities 4.92b |
| Total Rating: 4.83 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 80.64
| 1. Piotroski 6.0pt |
| 2. FCF Yield 4.54% |
| 3. FCF Margin 16.65% |
| 4. Debt/Equity 0.56 |
| 5. Debt/Ebitda 1.49 |
| 6. ROIC - WACC (= 7.64)% |
| 7. RoE 17.86% |
| 8. Rev. Trend 86.70% |
| 9. EPS Trend 46.99% |
What is the price of CHD shares?
Over the past week, the price has changed by +1.36%, over one month by +1.42%, over three months by -7.20% and over the past year by -21.69%.
Is CHD a buy, sell or hold?
- Strong Buy: 7
- Buy: 2
- Hold: 10
- Sell: 4
- Strong Sell: 1
What are the forecasts/targets for the CHD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 97 | 13.8% |
| Analysts Target Price | 97 | 13.8% |
| ValueRay Target Price | 79.1 | -7.1% |
CHD Fundamental Data Overview November 24, 2025
P/E Trailing = 26.5047
P/E Forward = 22.2717
P/S = 3.333
P/B = 4.7776
P/EG = 1.938
Beta = 0.452
Revenue TTM = 6.14b USD
EBIT TTM = 1.14b USD
EBITDA TTM = 1.39b USD
Long Term Debt = 2.20b USD (from longTermDebt, last quarter)
Short Term Debt = 32.4m USD (from shortTermDebt, last fiscal year)
Debt = 2.37b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.07b USD (from netDebt column, last quarter)
Enterprise Value = 22.53b USD (20.47b + Debt 2.37b - CCE 305.3m)
Interest Coverage Ratio = 9.73 (Ebit TTM 1.14b / Interest Expense TTM 117.0m)
FCF Yield = 4.54% (FCF TTM 1.02b / Enterprise Value 22.53b)
FCF Margin = 16.65% (FCF TTM 1.02b / Revenue TTM 6.14b)
Net Margin = 12.74% (Net Income TTM 782.5m / Revenue TTM 6.14b)
Gross Margin = 44.44% ((Revenue TTM 6.14b - Cost of Revenue TTM 3.41b) / Revenue TTM)
Gross Margin QoQ = 45.06% (prev 42.95%)
Tobins Q-Ratio = 2.46 (Enterprise Value 22.53b / Total Assets 9.14b)
Interest Expense / Debt = 1.97% (Interest Expense 46.8m / Debt 2.37b)
Taxrate = 22.86% (54.0m / 236.2m)
NOPAT = 878.5m (EBIT 1.14b * (1 - 22.86%))
Current Ratio = 1.09 (Total Current Assets 1.63b / Total Current Liabilities 1.50b)
Debt / Equity = 0.56 (Debt 2.37b / totalStockholderEquity, last quarter 4.22b)
Debt / EBITDA = 1.49 (Net Debt 2.07b / EBITDA 1.39b)
Debt / FCF = 2.02 (Net Debt 2.07b / FCF TTM 1.02b)
Total Stockholder Equity = 4.38b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.56% (Net Income 782.5m / Total Assets 9.14b)
RoE = 17.86% (Net Income TTM 782.5m / Total Stockholder Equity 4.38b)
RoCE = 17.29% (EBIT 1.14b / Capital Employed (Equity 4.38b + L.T.Debt 2.20b))
RoIC = 13.34% (NOPAT 878.5m / Invested Capital 6.59b)
WACC = 5.70% (E(20.47b)/V(22.84b) * Re(6.18%) + D(2.37b)/V(22.84b) * Rd(1.97%) * (1-Tc(0.23)))
Discount Rate = 6.18% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -0.22%
[DCF Debug] Terminal Value 79.39% ; FCFE base≈962.4m ; Y1≈1.04b ; Y5≈1.29b
Fair Price DCF = 93.82 (DCF Value 22.53b / Shares Outstanding 240.1m; 5y FCF grow 9.21% → 3.0% )
EPS Correlation: 46.99 | EPS CAGR: 6.48% | SUE: 1.55 | # QB: 2
Revenue Correlation: 86.70 | Revenue CAGR: 4.00% | SUE: 2.21 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.97 | Chg30d=+0.024 | Revisions Net=+9 | Analysts=14
EPS current Year (2025-12-31): EPS=3.49 | Chg30d=+0.013 | Revisions Net=+14 | Growth EPS=+1.5% | Growth Revenue=+1.5%
EPS next Year (2026-12-31): EPS=3.76 | Chg30d=+0.013 | Revisions Net=+4 | Growth EPS=+7.6% | Growth Revenue=+4.0%
Additional Sources for CHD Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle